Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United States and the first product to launch for this indication since Eylea in 2011. Beovu offers the potential for dosing once every 12 weeks immediately after the first three monthly doses, giving the product a dosing advantage over Lucentis and Eylea in its product labeling. Additionally, Beovu was found to be superior to Eylea in improving some anatomical outcomes in pivotal clinical trials. A competitive price from Novartis, coupled with the possibility of a less-burdensome dosing frequency, will likely ease Beovu’s incorporation into clinical practice. This report provides a snapshot of Beovu’s performance based on physician responses three months after its launch.
- What are the awareness of, familiarity with, and perceptions related to Beovu among U.S. ophthalmologists / retinal specialists three months after launch?
- Is Beovu being prescribed to treatment-naive patients or as a switch therapy? What are the reasons for prescribing Beovu for wet AMD, and how satisfied are prescribers with the product?
- What are the main obstacles holding physicians back from administering Beovu to more of their wet AMD patients? Why have some physicians not yet used Beovu for wet AMD?
- What promotional messages and activities is Novartis using to support Beovu’s launch for wet AMD?
Geography: United States
Primary Research: Survey of 75 U.S. ophthalmologists / retinal specialists in January 2020
Key metrics included: Unaided and aided awareness of Beovu; familiarity with and impressions of Beovu; prescriber and nonprescriber profiles; willingness to prescribe Beovu; performance of Beovu on key attributes; sales representative visit frequency, reach, and effectiveness; benchmarking against Eylea
DRG’s Special Topics reports assess key trends in dynamic disease areas. Here we provide a snapshot of Beovu’s performance at three months postlaunch in the U.S. wet AMD market. Specifically, we assess U.S. physicians’ awareness, perceptions, and usage of Beovu, as well as its current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts by Novartis, prescriber and nonprescriber profiles, and benchmarking against Eylea three months after it launched for wet AMD.
- Dry And Wet Age-Related Macular Degeneration - Special Topics - Special Topics - Beovu - Three Months Postlaunch For Wet AMD (US)
Author(s): Emma McFadden, PhD
Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy.
Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.